Erratum: Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

Schmitz, M; Temme, A; Senner, V; Ebner, R; Schwind, S; Stevanovic, S; Wehner, R; Schackert, G; Schackert, H K; Fussel, M; Bachmann, M; Rieber, E P; Weigle, B

doi:10.1038/sj.bjc.6603802

Cited by 19 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upregulation of Sox2 has been demonstrated in early pancreatic cancer lesions (Prasad et al, 2005) and in the human gastrointestinal tract (Long and Hornick, 2009). Sox2 has been associated with an immature phenotype in central nervous system teratomas (Phi et al, 2007) and glioblastomas (Schmitz et al, 2007). Furthermore, Sox2 knockdown arrested proliferation, resulting in a loss of tumorigenicity of glioblastoma CSCs (Gangemi et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Over-Expression of Oct4 in Human Esophageal Squamous Cell Carcinoma

Zhou

Huang

2011

Molecules and Cells

View full text Add to dashboard Cite

The Octamer 4 gene (Oct4) is a master pluripotency controller that has been detected in several types of tumors. Here, we examine the expression of Oct4 in human esophageal squamous cell carcinoma (ESCC). We found that punctate Oct4 protein was expressed in most (93.7%) ESCC samples but it was not observed in esophageal mucosa. Some ESCC cells had the capacity to form tumorospheres; those with an Oct4 + -rich cell phenotype had increased proliferation and Oct4 mRNA levels compared to those of differentiated cells in culture or xenograft tumors. The over-expression of Oct4 in ESCCs suggests that it is a potential target for ESCC therapy. Oct4 could be a useful tumor marker in an immunohistochemical panel designed to differentiate between ESCC and esophageal mucosa. Expression of Oct4 in tumorospheres might indicate the presence of a population of ECSCs and its expression in xenograft tumors suggests that Oct4 is also associated with tumor metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Over-Expression of Oct4 in Human Esophageal Squamous Cell Carcinoma

Zhou

Huang

2011

Molecules and Cells

View full text Add to dashboard Cite

show abstract

“…SOX2 is not only a prognostic indicator in these cancers but also a candidate for cancer stem-like cell/tumor-initiating cell-targeting T-cell-based immunotherapy. 30 The purpose of this study was therefore to evaluate the relationship between cancer stem-like cells/tumor-initiating cells and prognosis in upper urinary tract urothelial cell carcinoma by using the putative markers, ALDH1 and SOX2, with full clinicopathological data and follow-up. We also analyzed the association between cancer stem-like cell/tumor-initiating cell marker expression and recurrence, especially intravesical recurrence after radical nephroureterectomy.…”

mentioning

confidence: 99%

Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract

et al. 2013

View full text Add to dashboard Cite

Aldehyde dehydrogenase 1 (ALDH1) and sex determining region-Y-related high mobility group box 2 (SOX2) have been identified as putative cancer stem-like cell/tumor-initiating cell markers in various cancer tissues. The aim of this study was to elucidate the prognostic impact of these putative cancer stem-like cell/tumorinitiating cell markers in upper urinary tract urothelial cell carcinoma. Immunohistochemical staining for ALDH1 and SOX2 was carried out on archival specimens from 125 patients with upper urinary tract urothelial cell carcinoma who underwent radical nephroureterectomy. The prognostic value of ALDH1 and SOX2 expression and other clinicopathological features was evaluated. On univariate analysis, tumor grade, pathological T stage, pathological N stage, lymphovascular invasion, ALDH1 expression and SOX2 expression were associated with a poor prognosis. On multivariate analysis, the independent factors of prognosis were tumor grade (P ¼ 0.014), pathological N stage (P ¼ 0.005) and ALDH1 expression (P ¼ 0.002). In subgroup analysis, those subgroups with no positive, one positive or two positive results in immunohistochemistry for ALDH1 and SOX2 expression had estimated 5-year cancer-specific survival rates of 80%, 49% and 22%, respectively (Po0.001). Neither ALDH1 nor SOX2 expression correlated with intravesical recurrence after radical nephroureterectomy. These findings suggest that cancer stem-like cells/tumor-initiating cells are linked to more aggressive behavior of upper urinary tract urothelial cell carcinoma, supporting the current cancer stem cell hypothesis. Thus, therapeutic targeting of cancer stem-like cells/tumor-initiating cells in upper urinary tract urothelial cell carcinoma is a future possibility.

show abstract

“…The transcription factor SOX2 is an essential gene due to its role in sustaining growth and selfrenewal of several stem cell types, both embryonic and adult (31,32). In addition, it has been found to be expressed in a variable percentage of cells in several malignant tissues (33,34). We found that SOX2, not previously studied in neuroblastoma, was expressed in most of the neuroblastoma cell lines analyzed.…”

Section: Discussionmentioning

confidence: 61%

Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines

et al. 2010

View full text Add to dashboard Cite

Abstract. Neuroblastoma is the most common extracranial solid tumor in children, accounting for up to 10% of all childhood malignancies. Cellular heterogeneity is a hallmark of this embryonal cancer, as distinct neural crest lineages can be found within the same tumor sample. The aim of our study was to investigate the presence of a subpopulation of immature cells with features of cancer-like stem cells in 10 neuroblastoma cell lines. RT-PCR and flow cytometry were performed in order to analyze different kinds of 'stemness genes' such as: NESTIN (NES), CD133, SOX-2, BMI1, c-KIT, MELK1, MUSASHI-1 (MSI1), FAS, CD44 and VIMENTIN (VIM). In addition, glial and neuronal markers such as NCAM1, GFAP and B-TUBULIN III (TUBB3) were analyzed. Epigenetic changes within the CD133 (Prominin-1) gene promoter were also analyzed. Neuroblastoma cell lines showed a particular pattern of expression, suggesting the presence of an immature cancer stem cell-like subpopulation. The CD133 protein, commonly used to enrich putative cancer propagating stem cell-like populations in different kinds of solid tumors, presented a half-methylated DNA state in 7 of the 12 neuroblastoma cell lines analyzed. An increase in RNA and protein levels of CD133 was achieved following demethylation by assays using 5-aza-2'-deoxycytidine (5-Aza-dC). Since cancer stem cells are believed to be responsible for tumor metastasis, escape from anticancer therapies and disease relapse, their therapeutic targeting and analysis is crucial in neuroblastoma. Moreover, the regulation of CD133 by epigenetic changes may provide an innovative mechanism of CD133 expression as its regulation still remains unclear.

show abstract

Erratum: Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy

Cited by 19 publications

References 0 publications

Over-Expression of Oct4 in Human Esophageal Squamous Cell Carcinoma

Over-Expression of Oct4 in Human Esophageal Squamous Cell Carcinoma

Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract

Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines

Contact Info

Product

Resources

About